logo
  

Stock Alert: Corvus Pharma Surges 111%; Study Initiated For COVID-19 Treatment

Shares of Corvus Pharmaceuticals, Inc. (CRVS) more than doubled on Tuesday morning after the clinical stage biopharmaceutical company said it commenced a Phase 1 clinical study testing a novel treatment for COVID-19.

CRVS is currently trading at $5.80, up $3.06 or 111.68%, on the Nasdaq.

Corvus announced that it has initiated an early-state study to investigate a novel immunotherapy approach for patients with COVID-19. The study is expected to enroll up to 30 patients at several sites in the United States.

The enrollment follows the FDA's review and acceptance of the company's investigational new drug application for the COVID-19 study.

Corvus is studying an agonistic (immunostimulatory) humanized monoclonal antibody, designated as CPI-006, which has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Stocks fluctuated in morning trading on Friday before once again coming under pressure over the course of the afternoon. The major averages extended the sharp pullback seen on Thursday, ending the session at their lowest closing levels since late 2020. Consumer sentiment in the U.S. improved by less than initially estimated in the month of September, according to revised data released by the University of Michigan on Friday. The University of Michigan said the consumer sentiment index for September was downwardly revised to 58.6 from the preliminary estimate of 59.5. Chicago-area business activity unexpectedly contracted in the month of September, according to a report released by MNI Indicators on Friday. MNI Indicators said its Chicago business barometer slumped to 45.7 in September from 52.2 in August, with a reading below 50 indicating contraction. Economists had expected the business barometer to edge down to 51.8.
Follow RTT